{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T12:46:48Z","timestamp":1791809208850,"version":"4.3.4"},"reference-count":23,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T00:00:00Z","timestamp":1789084800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thegreenjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Radiotherapy and Oncology"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.radonc.2026.111780","type":"journal-article","created":{"date-parts":[[2026,9,13]],"date-time":"2026-09-13T14:12:45Z","timestamp":1789308765000},"page":"111780","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Patient-clinician symptom agreement before and after radiotherapy for prostate cancer: results from the randomized HYPO-RT-PC study"],"prefix":"10.1016","volume":"224","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2644-4246","authenticated-orcid":false,"given":"Ulrika","family":"R\u00f6nning\u00e5s","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6684-6816","authenticated-orcid":false,"given":"Lars","family":"Beckman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4716-6660","authenticated-orcid":false,"given":"Anna-Karin","family":"Wennstig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1248-5581","authenticated-orcid":false,"given":"Per","family":"Fransson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.radonc.2026.111780_b0005","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.radonc.2026.111780_b0010","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1111\/bju.13036","article-title":"Patient-reported 'ever had' and 'current' long-term physical symptoms after prostate cancer treatments","volume":"116","author":"Gavin","year":"2015","journal-title":"BJU Int"},{"key":"10.1016\/j.radonc.2026.111780_b0015","first-page":"78","article-title":"Late adverse health outcomes and quality of life after curative radiotherapy + long-term ADT in prostate cancer survivors: comparison with men from the general population","volume":"37","author":"Foss\u00e5","year":"2022","journal-title":"Clin Transl Radiat Oncol"},{"key":"10.1016\/j.radonc.2026.111780_b0020","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/j.juro.2010.04.009","article-title":"Do perceptions of adverse events differ between patients and physicians? Findings from a randomized, controlled trial of radical treatment for prostate cancer","volume":"184","author":"Steinsvik","year":"2010","journal-title":"J Urol"},{"key":"10.1016\/j.radonc.2026.111780_b0025","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14071670","article-title":"A comparison between patient- and physician-reported late radiation toxicity in long-term prostate cancer survivors","volume":"14","author":"Nuijens","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.radonc.2026.111780_b0030","first-page":"34","article-title":"Assessing concordance between patient-reported and investigator-reported CTCAE after proton beam therapy for prostate cancer","volume":"31","author":"Kowalchuk","year":"2021","journal-title":"Clin Transl Radiat Oncol"},{"key":"10.1016\/j.radonc.2026.111780_b0035","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1007\/s00066-018-1395-y","article-title":"Patient- versus physician-reported outcomes in prostate cancer patients receiving hypofractionated radiotherapy within a randomized controlled trial","volume":"195","author":"Rammant","year":"2019","journal-title":"Strahlenther Onkol"},{"key":"10.1016\/j.radonc.2026.111780_b0040","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2022.11.015","article-title":"Comparing symptom reporting by prostate cancer patients and healthcare professionals in the international multicentre REQUITE study","volume":"178","author":"Heumann","year":"2023","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2026.111780_b0045","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/j.ijrobp.2016.11.008","article-title":"Acute and late adverse events associated with radical radiation therapy prostate cancer treatment: a systematic review of clinician and patient toxicity reporting in randomized controlled trials","volume":"97","author":"Holch","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2026.111780_b0050","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/S1470-2045(20)30581-7","article-title":"Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer (HYPO-RT-PC): patient-reported quality-of-life outcomes of a randomised, controlled, non-inferiority, phase 3 trial","volume":"22","author":"Fransson","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.radonc.2026.111780_b0055","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/S0140-6736(19)31131-6","article-title":"Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial","volume":"394","author":"Widmark","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.radonc.2026.111780_b0060","first-page":"187","article-title":"Reliability and responsiveness of a prostate cancer questionnaire for radiotherapy-induced side effects","volume":"9","author":"Fransson","year":"2001","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.radonc.2026.111780_b0065","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.esxm.2018.06.002","article-title":"Scandinavian prostate cancer patients\u2019 sexual problems and satisfaction with their sex life following anti-cancer treatment","volume":"6","author":"Martin Hald","year":"2018","journal-title":"Sex Med"},{"key":"10.1016\/j.radonc.2026.111780_b0070","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1007\/s11764-023-01473-3","article-title":"Patient-physician agreement on function and pain is associated with long-term outcomes in sarcoma: findings from a longitudinal study","volume":"19","author":"Ko\u0161ir","year":"2025","journal-title":"J Cancer Surviv"},{"key":"10.1016\/j.radonc.2026.111780_b0075","doi-asserted-by":"crossref","first-page":"69.e19","DOI":"10.1016\/j.urolonc.2013.10.005","article-title":"Measuring health-related quality of life in men with prostate cancer: a systematic review of the most used questionnaires and their validity","volume":"33","author":"Hamoen","year":"2015","journal-title":"Urol Oncol"},{"key":"10.1016\/j.radonc.2026.111780_b0080","unstructured":"National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE). U.S. Department of Health and Human Services; 2017."},{"key":"10.1016\/j.radonc.2026.111780_b0085","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/dju244","article-title":"Development of the National Cancer Institute's patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE)","volume":"106","author":"Basch","year":"2014","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.radonc.2026.111780_b0090","doi-asserted-by":"crossref","DOI":"10.1002\/cam4.70896","article-title":"Patient versus clinician reported symptoms agreement in advanced metastatic bladder cancer patients","volume":"14","author":"Annakib","year":"2025","journal-title":"Cancer Med"},{"key":"10.1016\/j.radonc.2026.111780_b0095","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/j.ijrobp.2015.02.021","article-title":"Systematic review of radiation therapy toxicity reporting in randomized controlled trials of rectal cancer: a comparison of patient-reported outcomes and clinician toxicity reporting","volume":"92","author":"Gilbert","year":"2015","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2026.111780_b0100","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1001\/jamaoncol.2022.0114","article-title":"Identifying patients whose symptoms are underrecognized during treatment with breast radiotherapy","volume":"8","author":"Jagsi","year":"2022","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.radonc.2026.111780_b0105","first-page":"41","article-title":"Patient-reported outcome use in oncology: a systematic review of the impact on patient-clinician communication","volume":"26","author":"Yang","year":"2018","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.radonc.2026.111780_b0110","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1377\/hlthaff.2015.1362","article-title":"Incorporating patient-reported outcomes into health care to engage patients and enhance care","volume":"35","author":"Lavallee","year":"2016","journal-title":"Health Aff (Millwood)"},{"key":"10.1016\/j.radonc.2026.111780_b0115","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1016\/j.annonc.2022.04.007","article-title":"The role of patient-reported outcome measures in the continuum of cancer clinical care: ESMO Clinical Practice Guideline","volume":"33","author":"Di Maio","year":"2022","journal-title":"Ann Oncol"}],"container-title":["Radiotherapy and Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167814026006201?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167814026006201?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T12:08:16Z","timestamp":1791806896000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167814026006201"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":23,"alternative-id":["S0167814026006201"],"URL":"https:\/\/doi.org\/10.1016\/j.radonc.2026.111780","relation":{},"ISSN":["0167-8140"],"issn-type":[{"value":"0167-8140","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Patient-clinician symptom agreement before and after radiotherapy for prostate cancer: results from the randomized HYPO-RT-PC study","name":"articletitle","label":"Article Title"},{"value":"Radiotherapy and Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.radonc.2026.111780","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"111780"}}